Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;90(3):801-811.
doi: 10.1111/bcp.15950. Epub 2023 Nov 29.

Prediction of C-reactive protein dynamics during meropenem treatment in neonates and infants

Hiie Soeorg  1 , Helgi Padari  2 , Mari-Liis Ilmoja  3 , Koit Herodes  4 , Karin Kipper  4 , Irja Lutsar  1 , Tuuli Metsvaht  1   2 ; Neo Mero Consortium
Affiliations
Free article

Prediction of C-reactive protein dynamics during meropenem treatment in neonates and infants

Hiie Soeorg et al. Br J Clin Pharmacol. 2024 Mar.
Free article

Abstract

Aims: C-reactive protein (CRP) is used to determine the effect of antibiotic treatment on sepsis in neonates/infants. We aimed to develop pharmacokinetic-pharmacodynamic (PKPD) model of meropenem and CRP in neonates/infants and evaluate its predictive performance of CRP dynamics.

Methods: Data from neonates/infants treated with meropenem in 3 previous studies were analysed. To the previously developed meropenem PK models, the addition of turnover, transit or effect compartment, delay differential equation PD models of CRP as a function of meropenem concentration or its cumulative area under the curve (AUC) were evaluated. The percentage of neonates/infants (P0.1 , P0.2 ) in whom the ratio of the fifth day CRP to its peak value was predicted with an error of <0.1 (<0.2) was calculated.

Results: A total of 60 meropenem treatment episodes (median [range] gestational age 27.6 [22.6-40.9] weeks, postnatal age 13 [2-89] days) with a total of 351 CRP concentrations (maximum value 65.5 [13-358.4] mg/L) were included. Turnover model of CRP as a function of meropenem cumulative AUC provided the best fit and included CRP at the start of treatment, use of prior antibiotics, study and causative agent Staphylococcus aureus or enterococci as covariates. Using meropenem population predictions and data available at 0, 24, 48, 72 h after the start of treatment, P0.1 (P0.2 ) was 36.4, 36.4, 60.6 and 66.7% (70.0, 66.7, 72.7 and 78.7%), respectively.

Conclusion: The developed PKPD model of meropenem and CRP as a function of meropenem cumulative AUC incorporating several patient characteristics predicts CRP dynamics with an error of <0.2 in most neonates/infants.

Keywords: inflammatory biomarker; meningitis; optimized dosing; pharmacokinetic-pharmacodynamic model; sepsis.

PubMed Disclaimer

References

REFERENCES

    1. Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106(8):745-752. doi:10.1136/archdischild-2020-320217
    1. Lutsar I, Chazallon C, Trafojer U, et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. PLoS ONE. 2020;15(3):e0229380. doi:10.1371/journal.pone.0229380
    1. Wagstaff JS, Durrant RJ, Newman MG, et al. Antibiotic treatment of suspected and confirmed neonatal sepsis within 28 days of birth: a retrospective analysis. Front Pharmacol. 2019;10:1191. doi:10.3389/fphar.2019.01191
    1. Cantey JB, Baird SD. Ending the culture of culture-negative sepsis in the neonatal ICU. Pediatrics. 2017;140(4):e20170044. doi:10.1542/peds.2017-0044
    1. Tang Girdwood S, Pavia K, Paice K, Hambrick HR, Kaplan J, Vinks AA. β-lactam precision dosing in critically ill children: current state and knowledge gaps. Front Pharmacol. 2022;13:5138. doi:10.3389/fphar.2022.1044683

Publication types